Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMIT-CD: Mirikizumab With or Without Tirzepatide in Crohn’s Disease and Obesity/Overweight
2024-520210-21-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease, obesity and Overweight comparing Mirikizumab + Tirzepatide with Mirikizumab + Placebo (2 arms). Primary endpoint: Composite clinical and endoscopic remission with weight reduction. Planned start Aug 2025; status: authorised.
02
Drugs
mirikizumabtirzepatide
03
Conditions
Crohn's diseaseobesityOverweight
Beyond the preview
Go deeper on 2024-520210-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520210-21-00.